Aileron Therapeutics (NASDAQ:ALRN) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Aileron Therapeutics (NASDAQ:ALRN) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “

Other research analysts have also issued research reports about the stock. William Blair reiterated an outperform rating on shares of Aileron Therapeutics in a research note on Monday, May 6th. Canaccord Genuity dropped their price objective on shares of Aileron Therapeutics to $5.00 and set a buy rating on the stock in a research note on Tuesday, April 9th. Finally, HC Wainwright began coverage on shares of Aileron Therapeutics in a research note on Monday, March 11th. They issued a buy rating and a $7.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $4.67.



ALRN stock opened at $0.91 on Tuesday. Aileron Therapeutics has a 52-week low of $0.52 and a 52-week high of $6.18. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.38.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.13). As a group, analysts expect that Aileron Therapeutics will post -1.11 earnings per share for the current year.

In other Aileron Therapeutics news, major shareholder Bioventures Ltd Novartis sold 127,150 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $1.86, for a total value of $236,499.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. 16.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Blair William & Co. IL acquired a new position in Aileron Therapeutics in the 1st quarter valued at approximately $43,000. Renaissance Technologies LLC acquired a new position in Aileron Therapeutics in the 3rd quarter valued at approximately $137,000. Vanguard Group Inc increased its stake in Aileron Therapeutics by 8.0% in the 3rd quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock valued at $265,000 after buying an additional 7,109 shares during the period. Deutsche Bank AG increased its stake in Aileron Therapeutics by 432.9% in the 4th quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after buying an additional 104,932 shares during the period. Finally, Morgan Stanley increased its stake in Aileron Therapeutics by 2.9% in the 1st quarter. Morgan Stanley now owns 398,139 shares of the company’s stock valued at $776,000 after buying an additional 11,213 shares during the period. Hedge funds and other institutional investors own 29.17% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.